Relapsed Classical Hodgkin Lymphoma

Also known as: Relapsed Classical Hodgkin's Lymphoma / Relapsing classical Hodgkin lymphoma / Classical Hodgkin lymphoma recurrent / Relapsing classical Hodgkin lymphoma (disorder)

Drug	Drug Name	Drug Description
DB09035	Nivolumab	A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.
DB09037	Pembrolizumab	A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.

Drug	Drug Name	Target	Type
DB09035	Nivolumab	Programmed cell death protein 1	target
DB09035	Nivolumab	Programmed cell death 1 ligand 1	target
DB09037	Pembrolizumab	Programmed cell death protein 1	target
DB09037	Pembrolizumab	Programmed cell death 1 ligand 1	target

Drug	Drug Name	Phase	Status	Count
DB16225	Magrolimab	2	Recruiting	1
DB09037	Pembrolizumab	2	Recruiting	1